Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a web program help dementia caregivers sleep?

NCT ID NCT07836491

Symptom relief Sponsor: University of Missouri-Columbia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 23, 2026 · Last updated Sep 24, 2026 · Updated 1 time

Summary

Many people who care for a spouse with Alzheimer's disease or another dementia struggle with insomnia. Researchers at the University of Missouri-Columbia are testing an online program called SHUTi-DC, which delivers cognitive behavioral therapy for insomnia through eight weekly modules adapted for dementia caregivers. The study enrolls 80 spousal caregivers with insomnia symptoms. Half receive SHUTi-DC and half receive a web-based sleep education program, and everyone reports on their sleep and well-being before, during, and after the program.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an online cognitive behavioral therapy for insomnia program adapted for dementia caregivers
What this could lead to
If it works, this could give spousal dementia caregivers a way to treat insomnia at home without waiting for a trained therapist.
What could go wrong
The trial is small and early, and an online program may not suit everyone. Caregivers with other sleep disorders or serious health issues are not included, so results may not apply to all.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Spousal caregiver of a person with a clinician-diagnosed Alzheimer's disease or related dementia, with both partners cohabiting in the community * Clinically meaningful insomnia symptoms, defined as an Insomnia Severity Index (ISI) score of 8 or higher * Regular internet access and ability to independently use a computer or smartphone * Fluent in English * Residing within the United States Exclusion Criteria: * Parasomnia symptoms, including dream enactment or injurious nocturnal behaviors suggestive of REM sleep behavior disorder * Night-shift work, indicating primary circadian misalignment rather than insomnia * Current behavioral or psychological treatment for insomnia * Severe psychiatric conditions, such as current mania or hypomania, that would interfere with participation or safety * Significant cognitive impairment in the caregiver that would limit ability to engage in study procedures * Medical conditions that substantially affect sleep or safety, including neurodegenerative disease, stroke, traumatic brain injury, epilepsy, severe respiratory disease, pregnancy, or breastfeeding * Sleep difficulties fully attributable to caregiving tasks without underlying insomnia mechanisms

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Insomnia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

insomnia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Insomnia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.